ÜBER DIESE EPISODE
The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?
Guests:
- Tay Salimullah, Chief Access Commercial Officer at Novartis
- Jason Jones, Global Business Development Lead at Cellular Origins
Englisch
Vereinigte Staaten
TRANSKRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
VERGANGENE FOLGEN SUCHEN
Vorhandene Folgen von Invent: Life Sciences durchsuchen.
WEITERE EPISODEN IN DIESEM PODCAST
Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and product…
Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry.
We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future …
Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufactu…
Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.
With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this…
Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von TTP plc, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.
BEARBEITEN
Vielen Dank, dass Sie uns helfen, die Podcast-Datenbank auf dem neuesten Stand zu halten.
